How to mitigate the risks involved in highly potent APIs.

Why we need to shift from reactive to proactive measures in tackling global health challenges.

How can pharma improve patient access to medications? Christine Marsh of Boehringer Ingelheim offers her view.

How prefilled syringes, blow-fill-seal technology, and innovations in vials are transforming sterile manufacturing.

Regular injections to the eye are a reality for many patients. We must come up with better solutions for retinal degenerative diseases.

Choosing which medical congresses to target when launching your new medicine requires careful research and a sound strategy.

The pipeline of early-stage CRISPR therapeutics is huge, but advancing these innovations will require a multifaceted strategy.

Claus Zieler reflects on his time at Astellas and his role at EFPIA.

An HBV gene editing clinical trial has been approved in Moldova, but the challenges go beyond science and industry.

Maintaining the stability of vaccines over time and during temperature excursions is a crucial aspect of production, transport, and delivery.